ZIM Laboratories Limited Q2 & H1 FY26 Concall Decoded: ₹887 crore revenue, EU-GMP still missing, but optimism fully intact
1. Opening Hook
Just when pharma investors thought EU-GMP suspensions couldn’t get more dramatic, ZIM Laboratories decided to add HVAC logbooks to the villain list. Yes, a pen left inside a register managed to freeze Europe, stall innovation revenues, and hijack half the concall.
Management insists there was “no fraud, only bad handwriting habits,” while investors quietly Googled CAPA timelines. The quarter itself wasn’t terrible—revenues bounced back sequentially, losses narrowed, and pharma did the heavy lifting while Nutra took a nap.
But make no mistake, this concall wasn’t about numbers. It was about trust, timelines, and whether March 2026 is destiny or just another optimistic date on a PowerPoint.
Stick around. The EU story gets messier, funnier, and more revealing as we go.
2. At a Glance
Revenue ₹887 crore: Sequentially up 23.6%, because Q1 set the bar politely low.
Pharma 83% of sales: The adult in the room carried the entire household.
EBITDA ₹78 crore: Margins improved to 8.8%, proving cost control still exists.
PAT loss ₹4 crore: Almost profitable—just tripped near the finish line.
Nutra revenue dipped: Institutional buyers said “call you later.”
R&D spend ₹76 crore: Innovation continues, despite Europe pressing pause.
3. Management’s Key Commentary
“EU-GMP remediation remains our highest strategic priority.” (Translation: Everything else can wait, Europe is still angry.) 😏
“CAPA has been accepted and three action taken reports have been submitted.” (Paperwork is winning, reality pending.)
“There was no intention to commit fraud.” (It was a pen, not a conspiracy.)
“The observation was secondary and related to manual documentation.” (Excel files would’ve saved us millions.)
“We expect the EU-GMP audit by March 2026.” (Management’s favourite month, pending regulator mood.)
“Supplies could resume by Q1 or Q2 FY27.” (Translation: Not this year, please stop asking.)
“Pharma segment showed strong sequential growth.” (Base business refuses to die, thankfully.)
“Nutra demand will normalize in H2.” (Institutions are ‘thinking about it.’)
“Margins may take a marginal hit due to site transfers.” (CMOs don’t work for free.)
“FY26 revenues should be broadly in line with FY25.” *(Survival mode activated, growth postponed.) 😐
